The Sanofi/Translate team hits the green light on an early-stage study for their mRNA Covid-19 vaccine after seeing it work in animals
Sanofi and their mRNA vaccine partners at Translate Bio say they got the preclinical animal data on the Covid-19 antibodies they were looking for, beating out convalescent serum. And that clears the way to a Phase I/II launch before the end of this year.
The partners are well behind the lead mRNA vaccines from Pfizer/BioNTech and Moderna, both still in the running to offer pivotal data in the next weeks. But Sanofi is pursuing a variety of approaches to Covid-19, including an alliance with GSK on a more traditional approach to vaccine development.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,000+ biopharma pros reading Endpoints daily — and it's free.